When Brad Kahl was a young intern rotating through the various specialties in medical school, he met a professor/physician who showed him that he could make a real difference in patients’ lives in the field of hematology/oncology.  Thus Dr. Kahl’s’career path was launched, and he’s been making that difference in all our lives ever since.

 

Dr. Kahl says that he was drawn to the medical field because it provided the opportunity to make deep connections with patients, but he also loved research because it gave him the opportunity to help solve some of the issues that patients face.  Hematology/oncology gave him the opportunity do both.

 

Dr. Kahl grew up in Madison, Wisconsin where he received his undergraduate degree from the University of Wisconsin (UW). He received his medical degree from Tufts University in Boston where h was elected AOA then returned to Madison and UW for his internship, residency and hematology fellowship. 

 

Just a year after completing his fellowship, Dr. Kahl was appointed the Director of UW Lymphoma Service, a position he continues to hold.  He has served, and continues to serve, in leadership positions on several national and international committees, including serving as chair of the ECOG (Eastern Cooperative Oncology Group) Lymphoma Committee.

 

Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.

 

Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials. He has numerous publications related to his lymphoma research and serves on the editorial board for Clinical Advances in Hematology and Oncology and the Journal of Clinical Oncology. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group.

 

Dr. Kahl is the principal investigator in the RESORT (Ritiximab Extended Schedule Or Re-Treatment Trial) trial which was designed to determine whether, after induction therapy with Rituximab, it was better to give Rituximab as maintenance therapy or to re-treat with it as necessary.  The results showed that the two strategies were nearly equivalent. "We believe the re-treatment strategy is the preferred option to help patients with low-tumor-burden FL manage their disease,” says Dr. Kahl.